PHAXIAM Therapeutics S.A. Basic And Diluted Earnings Loss Per Share
PHAXIAM Therapeutics S.A. reported Basic And Diluted Earnings Loss Per Share of -1.22 EUR/shares for the 6-month period ending 2021-06-30, per its 6-K filed 2021-09-20.
Discontinued › Income Statement › Earnings Per Share
ifrs-full:BasicAndDilutedEarningsLossPerShare · last filed 2021-09-20
| Period end | Basic And Diluted Earnings Loss Per Share 6 month | Basic And Diluted Earnings Loss Per Share 12 month |
|---|---|---|
| 2021-06-30 | -1.22 EUR/shares 6-K · filed 2021-09-20 | |
| 2020-12-31 | -3.99 EUR/shares 20-F · filed 2021-03-08 | |
| 2020-06-30 | -1.95 EUR/shares 6-K · filed 2021-09-20 | |
| 2019-12-31 | -3.49 EUR/shares 20-F · filed 2021-03-08 | |
| 2019-06-30 | -1.63 EUR/shares 6-K · filed 2020-09-21 | |
| 2018-12-31 | -2.13 EUR/shares 20-F · filed 2021-03-08 | |
| 2018-06-30 | -1.06 EUR/shares 6-K · filed 2019-09-26 | |
| 2017-12-31 | -2.95 EUR/shares 20-F · filed 2020-03-18 | |
| 2016-12-31 | -2.74 EUR/shares 20-F · filed 2019-03-29 | |
| 2015-12-31 | -2.16 EUR/shares 20-F/A · filed 2018-05-23 |